A ngiogenesis is a hypoxia-driven process that produces the vascular network during embryogenesis, mature wound healing, and disease progression in adult life. 1 Intercellular adhesion and signaling mediated by homophilic interaction of VE-cadherin proteins in endothelial adherens junctions (AJs) play key roles in maintaining endothelial barrier function and vascular homeostasis during and after angiogenesis. [2] [3] [4] [5] Gene ablation studies of VE-cadherin and associated proteins have revealed that junction strength dictates endothelial function and microvascular morphology and integrity. 6, 7 An important aspect in angiogenesis is the ability of endothelial cells (ECs) to dynamically modulate cell-cell adhesive state by regulating VE-cadherin availability at the cell membranes. Although reduced VE-cadherin-mediated cell-cell adhesion reduces microvascular stability, decrease in adhesive strength and disruption of endothelial AJs is required to allow ECs migration and neovessel sprouting during vascular expansion.
Endocytosis is a cellular process that is commonly used to alter bioavailability of cell surface proteins to modulate their functions. Endocytosis involves uptake of cell surface proteins in transport vesicles and sorting of vesicle cargo to either recycling or degradation compartments. By using Rab family Objective-Decrease in VE-cadherin adherens junctions reduces vascular stability, whereas disruption of adherens junctions is a requirement for neovessel sprouting during angiogenesis. Endocytosis plays a key role in regulating junctional strength by altering bioavailability of cell surface proteins, including VE-cadherin. Identification of new mediators of endothelial endocytosis could enhance our understanding of angiogenesis. Here, we assessed the function of CMTM3 (CKLF-like MARVEL transmembrane domain 3), which we have previously identified as highly expressed in Flk1 + vesicles. CMTM3 overexpression enhances, whereas CMTM3 knockdown decreases internalization of cell surface VE-cadherin in vitro. CMTM3 promotes loss of endothelial barrier function in thrombin-induced responses, shown by transendothelial electric resistance measurements in vitro. Conclusions-In this study, we have identified a new regulatory function for CMTM3 in angiogenesis. CMTM3 is involved in VE-cadherin turnover and is a regulator of the cell surface pool of VE-cadherin. Therefore, CMTM3 mediates cell-cell adhesion at adherens junctions and contributes to the control of vascular sprouting. Visual Overview-An online visual overview is available for this article. (Arterioscler Thromb Vasc Biol. 2017;37:1098
GTPases as markers for intracellular vesicular compartments, the transport route of the membrane proteins can be actively monitored. 8 Previous studies have indicated that p120-catenin regulates VE-cadherin lysosomal degradation by inhibiting endocytosis of the cell surface pool via interaction with the cytoplasmic tail of VE-cadherin proteins. 9 Further analysis revealed that P102-catenin acts as a key protein in the plasma membrane retention mechanism of VE-cadherin by preventing recruitment of VE-cadherin into membrane domains enriched with endocytic machinery proteins, including Clathrin. 10 Other studies also indicate that cell surface availability of VE-cadherin is regulated by VEGFA (vascular endothelial growth factor A) and is mediated by β arrestin 2 and Clathrin-dependent endocytosis. 4 Although endothelial endocytosis plays such a critical role in VE-cadherin and AJ regulation during and after angiogenesis, our overview of important regulators involved in these early endocytotic and subsequent intracellular transport processes is still far from complete. To identify new key regulators in angiogenesis and vascular homeostasis, we conducted a microarray screen on the transcriptome of murine embryos, comparing Flk + endothelial progenitor cells with Flk1− cell population. We identified CMTM3 (CKLF-like MARVEL transmembrane domain 3) as a putative candidate gene enriched in the Flk1 + endothelial progenitor cell population. CMTM3 is a member of the chemokine-like factor super family (CKLFSF [chemokine-like factor super family]/CMTM [CKLF-like transmembrane domain]) located on chromosome 16q22.1.
11 CMTM is a family of proteins linking chemokines and the TM4SF (transmembrane 4 super family), encoded by 9 genes in humans, CKLF, and CKLFSF1-8. 11 Previous reports have indicated that CMTM members play important roles in cancer development. 9, 12, 13 Furthermore, some members of the CMTM family are highly expressed in immune cells. 11, 14 For CMTM3, more recent reports indicate involvement of the protein in preventing growth and invasion of different types of cancer. [15] [16] [17] However, the putative function of CMTM3 in angiogenic regulation in ECs remains to be elucidated.
Here, we studied the angiogenic potential of CMTM3 and investigated the molecular pathways that are mediated by CMTM3 in ECs. Our findings indicate that CMTM3 promotes neovessel formation in vitro in a 3-dimensional (3D) collagen matrix-based coculture of primary vascular cells. Loss-offunction studies in vivo by morpholino silencing of the orthologue of CMTM3 in developing zebrafish larvae validate CMTM3 proangiogenic capacities. In vitro studies demonstrate that CMTM3 colocalizes with the early endosome markers (EEA1 [early endosome marker 1] and clathrin) and internalized VE-cadherin. CMTM3 overexpression in human umbilical vein endothelial cells (HUVECs) promotes endocytosis and intracellular vesicular trafficking and augments basal and VEGFA-induced internalization of VE-cadherin. In contrast, knockdown of CMTM3 in HUVECs significantly reduces VE-cadherin internalization. On the basis of these findings, we propose a model in which CMTM3 contributes to early endocytosis of VE-cadherin, a crucial step for reducing cell-cell adhesive strength in AJs to facilitate neovascular sprouting in the initial steps of angiogenesis. Our study provides new insights into the regulatory mechanisms by which endocytosis controls bioavailability of VE-cadherin in endothelial AJs and presents the first evidence of CMTM3-mediated control of early endocytosis of cell membrane surface proteins in vascular cells during angiogenesis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement. Figure 1A ). Expression levels of the other CMTM family members did not differ between groups, indicating that the siRNA-mediated silencing of CMTM3 was specific ( Figure 1B) . Next, the angiogenic capacities of these CMTM3-silenced ECs were evaluated in an in vitro 3-dimensional (3D) angiogenesis assay that was previously developed for studying the formation of lumenized microcapillary structures ( Figure 1C) . 18, 19 In this assay, GFP-labeled HUVECs and RFP (red fluorescent protein)-labeled pericytes were cocultured in a collagen matrix, which enabled direct interaction between the 2 cell types. EC sprouting and onset of tubule formation can be observed after 1 day of coculture. At the same time, stabilization of neovascular structures is triggered by perivascular recruitment of pericytes. Both processes proceed till 5 days post-seeding, eventually forming microcapillaries with pericyte coverage and clear distinction of open luminal areas ( Figure 1C ). Imaging and quantification of the vascular structures were conducted at days 2 and 5.
Results

CMTM3 Silencing in ECs Impairs
Data obtained at days 2 and 5 showed that CMTM3 silencing in GFP-HUVECs severely impaired formation of neovascular structures in the 3D vascular assay, compared with nontreated and sisham controls ( Figure 1D and 1E). CMTM3 silencing reduced total tubule length (by 4.6-and 3.9-fold at day 2 and by 2.7-and 2.6-fold at day 5), number of tubules (by 3.6-and 3.1-fold at day 2 and by 2.2-and 2.1-fold at day 5), number of junctions (by 10.2-and 7.5-fold at day 2 and by 4.8-and 4.7-fold at day 5), and mean tubule length (by 1.3-and 1.2-fold at day 2 and by 1.4-and 1.3-fold at day 5), compared with control and sisham, respectively. In contrast, CMTM3 silencing in RFP-pericytes did not affect neovascular growth, demonstrated by lack of differences between groups in vascular parameters at both time points ( Figure 1F) . Similarly, CMTM3 silencing in GFP-HUVECs using a second siRNA sequence significantly decreased total 
Mural Cell Interaction Induces Expression of CMTM3 and CMTM Family Members CKLF1, CMTM2, CMTM4, and CMTM8 in Human ECs
To investigate the CMTM3 expression in vascular cells, quantitative polymerase chain reaction was conducted on single cultured vascular cells and compared with cocultured human vascular cells that mimicked the physiological in vivo and coculture condition in which pericytes and ECs are in direct contact during angiogenesis and vascular homeostasis. CMTM3 was significantly upregulated in HUVECs in response to coculture with pericytes and vascular smooth muscle cells (Figure 2A and 2B). Further evaluation of the other CMTM family members showed upregulation of CMTM4 and CMTM8 in response to coculture with vascular smooth muscle cells or pericytes, whereas CMTM2 and CLKF1 were only upregulated in the vascular smooth muscle cells coculture condition ( Figure 2B ). CMTM3 expression was not altered in mural cells exposed to endothelial costimulation, whereas CMTM2, CMTM4, and CMTM8 expressions in mural cells were responsive to coculture with ECs. These findings indicate that CMTM3 and CMTM-family members are upregulated in response to endothelial and mural cell contact.
Silencing of CMTM3 During Zebrafish Development Inhibits Intersomitic Vessel Growth
To assess the involvement of CMTM3 in angiogenesis in vivo, the gene was silenced in developing zebrafish larvae of the transgenic zebrafish lines Tg(fli1:eGFP) y1 (transgene [Friend leukemia integration 1 transcription factor: enhanced green fluorescent protein]), using morpholino knockdown technology. CMTM3 and its family members are highly conserved in most species including the zebrafish. Two morpholinos were designed for silencing of the zebrafish CMTM3 orthologue based on the splice modification principle of the pre-mRNA target and were validated to produce (nonfunctional) alternative spice products (Figure IIA through IIC in the online-only Data Supplement). The first morpholino construct targeting the splice site located on CMTM3 exon 3-intron 3 (E3-I3) diminished intersomitic vessel (intersegmental vessel) formation at 24 hours post-fertilization compared with uninjected controls. Quantification of zebrafish phenotype showed that in the E3-I3 group, 47% of the larvae displayed the intersegmental vessel defect phenotype, versus 0% in the control group ( Figure 3A and 3C) . Functional validation of the E3-I3 morpholino was shown by polymerase chain reaction of mRNA extracted from injected pools of larvae, indicated by the presence and absence of the nonspliced premRNA band in E3-I3 and uninjected control groups, respectively ( Figure 3B) . Similarly, the second morpholino construct targeting the splice site on exon 2-intron 2 (E2-I2) inhibited the growth of intersegmental vessels, with the defect phenotype consistently observed in 67% of the E2-E2 group versus 0% in the uninjected control group, further validating the negative effect of CMTM3 silencing on angiogenesis during zebrafish development ( Figure 3C ; Figure  IIA through IIF in the online-only Data Supplement).
CMTM3 Silencing Does Not Affect EC Proliferation and Cell Migration
Previous studies in gastric cancer cells imply that CMTM3 functions as a tumor suppressive gene with overexpression of CMTM3 leading to inhibition of cell proliferation and migration. Here, we investigated the effect of CMTM3 silencing on these specific parameters in HUVECs. Knockdown of CMTM3 mediated by siRNA targeting (siCMTM3) did not affect cell proliferation compared with nontransfected and scrambled nontargeting siRNA transfected controls (sisham), indicated by a lack of difference in cell count during HUVEC expansion during the course of 2 days ( Figure 4A ). In line with these results, no difference in cell cycle progression was observed between the groups ( Figure 4B and 4C). In addition, cell migration capacity was investigated in a transwell migration assay but showed no effect of CMTM3 silencing ( Figure 4D and 4E) . Similarly, migration and proliferation was not affected by CMTM3 overexpression in HUVECs, which was induced by transfection with a recombinant adenovirus encoding for human CMTM3 cDNA (adCMTM3; Figure III in the online-only Data Supplement). These data indicate that decrease in physiological levels of CMTM3 does not affect the proliferative and migratory capacity of human ECs.
CMTM3 Localizes in Distinct VesicleLike Structures and Colocalizes With VECadherin in the Endothelial Cytosol
To further elucidate the mechanistic function of CMTM3, HUVECs were transfected with a recombinant adenovirus encoding for human CMTM3 cDNA (adCMTM3). Transgene Figure 5A ). CMTM3 protein was detected by immunofluorescence staining in the cytosol where it accumulated in vesicle-like structures ( Figure 5B) . Western blot analysis also demonstrated that CMTM3 was present in the soluble cytosolic fraction and not in the insoluble actin bound fraction of HUVEC lysates ( Figure 5C ). To further elucidate the intracellular function of CMTM3, we assessed the colocalization of CMTM3 with markers of the different intracellular vesicular transport compartments. Double immunofluorescent staining of EEA1 (a marker of early endosomes) and CMTM3 in HUVECs transfected with an adenoviral expression vector of CMTM3 cDNA, showed significant colocalization between the 2 signals in the larger sized cytosolic vesicles ( Figure 5D ). Similarly, CMTM3 colocalized with larger vesicles that were positive for Clathrin ( Figure 5E ). In contrast, colocalizations between CMTM3 and Rab11 or Rab4 (both markers of recycling vesicles) and between CMTM3 and Rab7 (marker for vesicles destined to transport proteins to the lysosomal degradative pathway) or Rab5 (late endosome/lysosome protein) were limited ( Figure 5F through 5I). Intracellular trafficking of endocytic vesicles plays a crucial regulatory role in controlling cell surface presentation of VE-cadherin, a cell-cell AJ protein that is critical for vascular barrier function and angiogenesis. 10 Immunofluorescence staining of VE-cadherin in confluent endothelial monolayers of adCMTM3 transfected HUVECs (adCMTM3) showed that CMTM3 overexpression increased cytosolic localization of VE-cadherin compared with the mainly cell-cell junctional localization that was observed in controls transfected with sham adenovirus (adsham; Figure 5J ). Western blot analysis indicated that total protein levels of VE-cadherin remained unchanged ( Figure 5K ). Double staining of CMTM3 and VE-cadherin in adCMTM3 HUVECs showed significant colocalization of CMTM3 with cytosolic VE-cadherin ( Figure 5L 
CMTM3 Mediates VE-Cadherin Endocytosis and Barrier Function of Endothelial (Adherens) Junctions
To elucidate the role of CMTM3 in the internalization of VE-cadherin, we conducted an internalization assay . Thus, these data confirm that CMTM3 is indeed involved in VE-cadherin internalization. To investigate whether VE-cadherin uptake was mediated by direct binding to CMTM3, coimmunoprecipitation experiments were conducted using magnetic beads coated with an antibody against VE-cadherin to isolate VE-cadherin complexes in protein lysate of adCMTM3-transfected HUVECs.
VE-cadherin protein pull down was successful, but no CMTM3 was detected in the coimmunoprecipitate, implying that direct binding between CMTM3 and VE-cadherin does not take place in HUVECs ( Figure VIII in the onlineonly Data Supplement). Shifts in VE-cadherin endocytosis directly alter cellsurface bioavailability of VE-cadherin to form intercellular homophilic bonds at AJs and may, therefore, impact endothelial barrier function. To evaluate the effect of CMTM3 on the barrier function, we conducted transendothelial electric resistance measurements on HUVEC monolayers exposed to thrombin-induced endothelial junction disruption. Basal levels of electric resistance did not differ between siCMTM3 and sisham groups. However, the thrombininduced response in CMTM3 knockdown was significantly decreased compared with sisham controls ( Figure 8A ): The decrease in resistance during the initial phase (0-30 minutes, exposure to thrombin) was less for siCMTM3 (P<0.1; Figure 8B ), whereas the increase in resistance during the recovery phase (30-120 minutes, after removal of thrombin at 30 minutes) was not significantly different between the 2 groups ( Figure 8C ). In contrast, whereas basal levels were similarly not affected, CMTM3 overexpression significantly increased the thrombin-induced response ( Figure 8D ): the decrease in resistance during the initial phase was significantly higher for adCMTM3 compared with adsham controls ( Figure 8E) . Similarly, the increase in resistance during the restoration phase was more pronounced in the adCMTM3 group ( Figure 8F ).
Discussion
We have previously found that CMTM3 expression is enriched in endothelial progenitor cells during murine embryonic development. In this study, we assessed the endothelial function of this putative angiogenic regulator. The most important findings of our current study are as follows: (1) 
CMTM3 Regulation of VE-Cadherin Turnover in Angiogenesis
Previously, CMTM family members have been shown to regulate tumor cell growth and migration in different types of cancers. 9, 12, 13 For CMTM3, it has been reported that the protein was highly expressed in testis, leukocytes, and spleen. 11 In cancer cells, CMTM3 was silenced by CpG methylation in carcinomas, and restoration of CMTM3 expression inhibited tumor cell growth and promoted apoptosis.
17 CMTM3 silencing or downregulation was also reported for testicular and gastric cancer cells. Similarly, restoration of CMTM3 expression inhibited cancer cell growth by inducing cell cycle arrest and reducing cancer cell migration. 15, 20 However, the function of CMTM3 in normal cell types, and in particular, in vascular cells, remained yet to be defined.
In this study, we demonstrated that CMTM3 plays an important role in angiogenesis in vivo and in vitro. In contrast to the main CMTM3 function in various cancer cell types, our data showed that CMTM3 does not influence cell cycle progression and proliferation in ECs. Furthermore, CMTM3 does not affect EC migration. Rather, our data demonstrated that the angiogenic capacity of CMTM3 is associated with the regulation of cell surface VE-cadherin bioavailability mediated by mechanisms of endocytosis.
Endocytosis-mediated internalization of VE-cadherin removes the protein from AJ sites and reduces formation of intercellular complexes. This decrease in cell-cell connections is vital for the initial phases of angiogenic sprouting, as destabilization of intercellular contacts promotes EC migration and tip and stalk cell differentiation, followed by vascular expansion from the pre-existing origin vessel. For example, knockdown of VE-cadherin in zebrafish embryos has been shown to increase intersomitic vessel sprouting. 21 Previous studies have also shown that AJ turnover involves endocytic trafficking pathways that essentially control the rate of VE-cadherin turnover: VE-cadherin internalization in response to, for example, VEGDA stimulation, is mediated by VE-cadherin targeting for Clathrin-mediated endocytosis by binding of (β-arrestin) adaptor protein-mediated complexes, which further recruits endocytic machinery protein clusters into Clathrin-coated pits situated in the membrane. 4 This is followed by dynamin-mediated scission of the plasma membrane, followed by inward membrane budding to form Clathrin-coated vesicles. 22 After internalization, these vesicles fuse into early endosomes where VE-cadherins are either sorted into late endosomes and subsequently degraded in lysosomes 23 or are transported back to the cell surface pool directly or via further processing by recycling endosomes. 16, 22 Here, we demonstrated that CMTM3 could promote the endocytosis pathway: Clathrin + subcellular vesicles and early endosomes marked by EEA1 were increased in CMTM3-expressing ECs compared with adsham controls. Furthermore, CMTM3 expression increased recycling endosomes marked by Rab11 and late endosomes marked by Rab7. We also showed that CMTM3 expression promotes internalization of VE-cadherin at basal level and in response to VEGFA stimulation, whereas CMTM3 knockdown inhibited VE-cadherin internalization in response to VEGFA. Furthermore, CMTM3-reduced junctional resistance in endothelial monolayers, indicating that CMTM3 regulates endothelial barrier function and vascular integrity.
In relation to endocytic mechanisms and subcellular vesicles trafficking, Eswaran et al 24 reported that the CMTMfamily genes were homologous to myelin and lymphocyte (myelin and lymphocyte) proteins tricellulins, plasmolipins, and occluding families, which comprise the tetra-spanin transmembrane domain (myelin and lymphocyte and related protein for vesicle trafficking and membrane linking or MARVEL [MAL and related proteins involved for vesicle trafficking and membrane link]). These proteins have been functionally linked to cell communication and intracellular transport. They also demonstrated that CMTM7 interacts with BLNK (B-cell linker) in a membrane protein complex in B-cell precursor acute lymphoblastic leukemia cell lines. 24 Overexpression of CMTM8 in tumor cell lines enhanced the endocytosis rate of epidermal growth factor receptor. 25 Further studies are required to assess whether the other family members, like CMTM3, are also involved in endocytosis regulation.
On the basis of our findings and previous reports, we interpret from our data that CMTM3 is involved in turnover of the cell surface VE-cadherin pool. In an angiogenic environment, formation of vascular sprouts from pre-existing vessels is mediated by VEGFA. Endocytosis of VE-cadherin after VEGFA stimulation is one of the main mechanisms by which VEGFA promotes vascular sprouting. 4 As indicated by our findings, CMTM3 seems to be an important regulator in this process as it significantly enhances VEGFA-mediated VE-cadherin, thereby reducing junctional adhesion strength between the cells. The exact mechanism by which CMTM3 facilitates VE-cadherin internalization remains to be further investigated. Given our findings that also demonstrated that CMTM3 is colocalized with Clathrin, CMTM3 could function as an adaptor protein that is involved in VE-cadherin targeting and positioning in the protein complex of Clathrin-mediated endocytosis. Similarly, CMTM3 could be involved in regulating the fusion of Clathrin-coated vesicles into EEA1 + endosomes, as CMTM3 also colocalized with EEA1 in our studies. Currently, we are conducting further studies to elucidate the contribution of CMTM3 in subcellular trafficking of VE-cadherin.
In conclusion, in this study, we have identified a regulatory function for CMTM3 in angiogenesis. CMTM3 is involved in VE-cadherin turnover and is a regulator of the cell surface pool of VE-cadherin. Therefore, CMTM3 mediates cell-cell adhesion at AJs and contributes to the control of vascular sprouting. Further studies that elucidate the exact mechanisms by which CMTM3 regulates endocytic transport of plasma membrane proteins in ECs could lead to the identification of new drug targets and contribute to new therapies to block vascular growth in tumors or enhance angiogenesis in tissue regeneration.
